-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Beam, Inc. (BEAM) Misses Q3 EPS by 5c
-
-
-
-
-
-
-
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
Beam Therapeutics Inc. (BEAM) Granted FDA Orphan Drug Designation for BEAM-101
-
-
-
-
-
-
-
BofA Securities Upgrades Beam Therapeutics Inc (BEAM) to Buy
-
-
-
-
-
-
-
Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy
-
-
-
-
-
-
-
Beam, Inc. (BEAM) Tops Q4 EPS by 18c
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

